- Home
- MPB vs KROS Comparison
MPB vs KROS Comparison
Compare MPB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- KROS
- Stock Information
- Founded
- MPB 1868
- KROS 2015
- Country
- MPB United States
- KROS United States
- Employees
- MPB N/A
- KROS N/A
- Industry
- MPB Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- KROS Health Care
- Exchange
- MPB Nasdaq
- KROS Nasdaq
- Market Cap
- MPB 641.4M
- KROS 558.9M
- IPO Year
- MPB N/A
- KROS 2020
- Fundamental
- Price
- MPB $30.22
- KROS $13.45
- Analyst Decision
- MPB Buy
- KROS Buy
- Analyst Count
- MPB 2
- KROS 13
- Target Price
- MPB $36.00
- KROS $20.63
- AVG Volume (30 Days)
- MPB 100.5K
- KROS 603.2K
- Earning Date
- MPB 07-23-2025
- KROS 08-06-2025
- Dividend Yield
- MPB 2.65%
- KROS N/A
- EPS Growth
- MPB 23.94
- KROS N/A
- EPS
- MPB 2.88
- KROS 0.11
- Revenue
- MPB $181,865,000.00
- KROS $214,713,000.00
- Revenue This Year
- MPB $24.31
- KROS $5,006.76
- Revenue Next Year
- MPB $13.74
- KROS N/A
- P/E Ratio
- MPB $10.50
- KROS $123.44
- Revenue Growth
- MPB 9.21
- KROS 91657.70
- 52 Week Low
- MPB $21.11
- KROS $9.12
- 52 Week High
- MPB $33.87
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- MPB 76.73
- KROS 43.42
- Support Level
- MPB $28.02
- KROS $13.24
- Resistance Level
- MPB $28.48
- KROS $13.77
- Average True Range (ATR)
- MPB 0.62
- KROS 0.38
- MACD
- MPB 0.35
- KROS -0.04
- Stochastic Oscillator
- MPB 99.52
- KROS 28.00
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.